Supernus Pharmaceuticals Regulatory Approval
The FDA has recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in advanced Parkinson’s disease. The exclusivity period is retroactive to the drug's approval date of February 3, 2025, and the company has also submitted an sNDA for a second supplier to ensure long-term supply stability.
- Term
- 7 years
“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”
Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals